Drugs / Levonadifloxacin
Levonadifloxacin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02244827 | Sep → Dec 2014 | liver disease, severe congenital | Wockhardt | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03405064 | Aug 2017 → Sep 2018 | — | Wockhardt | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levonadifloxacin | “levonadifloxacin (active drug) and the sulfate metabolite” NCT02244827 ↗ |
| Known as | (s)-(-)-nadifloxacin | ChEMBL registry synonym — accepted as the source's own label CHEMBL190561 ↗ |
| Known as | Levonadifloxacina | ChEMBL registry synonym — accepted as the source's own label CHEMBL190561 ↗ |
| Known as | Levonadifloxacine | ChEMBL registry synonym — accepted as the source's own label CHEMBL190561 ↗ |
| Known as | WCK-771 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL190561 ↗ |
| Modality | Small molecule | “belonging to the benzoquinolizine subclass of quinolone.” PMID 32738837 ↗ Aug 2020 |
| Route | Intravenous | “It is developed for oral or intravenous administration for the treatment of infections caused by Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA).” PMID 32738837 ↗ Aug 2020 |
| Route | Oral | “It is developed for oral or intravenous administration for the treatment of infections caused by Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA).” PMID 32738837 ↗ Aug 2020 |